Literature DB >> 22782645

Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.

Agnès Lillo-Le Louët, Martine Wolf, Lilia Soufir, Arnaud Galbois, Anne-Sylvie Dumenil, Georges Offenstadt, Meyer-Michel Samama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22782645     DOI： 10.1160/TH12-03-0149

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  17 in total

1.  Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.

Authors:  Manuel Quintana Díaz; Alberto M Borobia; Ma Angelica Rivera Núñez; Ana Maria Martínez Virto; Sara Fabra; Marcelino Sánchez Casado; Jose A García-Erce; C Meyer Samama
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 2.  Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

3.  A mouse bleeding model to study oral anticoagulants.

Authors:  Dougald M Monroe; Maureane Hoffman
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 4.  Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Authors:  Julie Kalabalik; Gail B Rattinger; Jesse Sullivan; Malgorzata Slugocki; Antonia Carbone; Anastasia Rivkin
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

5.  Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.

Authors:  Luca Masotti; Gianni Lorenzini; Cristiana Seravalle; Grazia Panigada; Giancarlo Landini; Roberto Cappelli; Sam Schulman
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

Review 6.  Enhanced elimination of dabigatran through extracorporeal methods.

Authors:  Nadia I Awad; Luigi Brunetti; David N Juurlink
Journal:  J Med Toxicol       Date:  2015-03

7.  Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Authors:  Meyer Michel Samama; Céline Guinet; Léna Le Flem; Emmanuel Ninin; Jean-Marc Debue
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

8.  The epidemic of pre-injury oral antiplatelet and anticoagulant use.

Authors:  A E Berndtson; R Coimbra
Journal:  Eur J Trauma Emerg Surg       Date:  2014-05-01       Impact factor: 3.693

9.  Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.

Authors:  Jovan P Antovic; Mika Skeppholm; Jaak Eintrei; Elisabet Eriksson Boija; Lisbeth Söderblom; Eva-Marie Norberg; Liselotte Onelöv; Yuko Rönquist-Nii; Anton Pohanka; Olof Beck; Paul Hjemdahl; Rickard E Malmström
Journal:  Eur J Clin Pharmacol       Date:  2013-06-20       Impact factor: 2.953

Review 10.  Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.

Authors:  Jonathan Douxfils; Helen Mani; Valentine Minet; Bérangère Devalet; Bernard Chatelain; Jean-Michel Dogné; François Mullier
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.